FibroBiologics presents research on artificial thymus organoids at the ThymUS 2025 Meeting, showcasing advancements in T-cell development.

The artificial thymus organoid has shown an ability to support distinct vascularization, critical for sustained functionality in vivo, while producing fully mature T cells expressing T cell receptors.

FibroBiologics is developing a fibroblast-based ATO in which cells from the thymus are combined with uniquely produced fibroblasts to create a T cell producing organoid.

On June 25, 2024, FibroBiologics, Inc. (NASDAQ:FBLG) announced positive proof-of-concept data regarding the development of a novel fibroblast-based artificial thymus organoid that can restore ...

The abstract entitled “A rapid and scalable thymus organoid development method for generating functional T cells” presents progress on the development of a transplantable and scalable ...

Recent results from the artificial thymus organoid program showed that fibroblasts and thymus-derived cell organoids can persist and function for over 50 days post-transplantation, with ...

The abstract entitled “A rapid and scalable thymus organoid development method for generating functional T cells” presents progress on the development of a transplantable and scalable ...

The artificial thymus organoid also produces T cells with diverse TCR-beta chains that enable the recognition of a broad spectrum of antigens. "This data further supports our unique approach to using ...